Cabaletta Bio Inc. (CABA)
Cabaletta Bio Inc. (CABA) Stock Price, Analysis & Data
| Bid | 1.98 |
| Market Cap | 466.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -181.32M |
| Beta | 3.25 |
| EPS (ttm) | -1.38 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.88 |
| P/B (ttm) | 2.19 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 16, 2026 |
| Ask | 3.4 |
| Volume | 2,352,224 |
| Avg. Volume (20D) | 4,328,477 |
| Open | 2.68 |
| Previous Close | 2.71 |
| Day's Range | 2.64 - 2.77 |
| 52-Week Range | 1.40 - 4.23 |
| Analyst | Strong Buy |
| Price Target | 13.5 (390.91%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenil...
Financial Performance
In 2025, Cabaletta Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -167.86M, an increase of 44.87%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for CABA stock is "Strong Buy". The 12-month stock price forecast is 13.5, which is upside of 390.91% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
